SYRA Syra Health Corp Forecast, Technical & Fundamental Analysis

SYRA's RSI Indicator peaks and leaves overbought zone

The 10-day RSI Oscillator for SYRA moved out of overbought territory on January 08, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 3 instances where the indicator moved out of the overbought zone. In of the 3 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 9 cases where SYRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SYRA broke above its upper Bollinger Band on January 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 27, 2024. You may want to consider a long position or call options on SYRA as a result. In of 22 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SYRA just turned positive on December 27, 2024. Looking at past instances where SYRA's MACD turned positive, the stock continued to rise in of 9 cases over the following month. The odds of a continued upward trend are .

SYRA moved above its 50-day moving average on December 27, 2024 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SYRA crossed bullishly above the 50-day moving average on January 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +6 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRA advanced for three days, in of 40 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.271) is normal, around the industry mean (4.533). P/E Ratio (0.000) is within average values for comparable stocks, (71.885). SYRA's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.595). SYRA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.026). P/S Ratio (1.255) is also within normal values, averaging (21.325).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SYRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.